TCR-T as an T-cell immunotherapy option for malignant hematology patients - Webinar

TCR-T as an T-cell immunotherapy option for malignant hematology patients - Webinar

New advances in clinical research has found that stimulating the natural defenses of a person’s immune system to kill cancer cells, known as immunotherapy, has become a novel and exciting approach to treat cancer with many positive outcomes for certain indications.

CAR T-cell Therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumor development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR-T) has also shown great potential.

Join our free webinar and listen to Dr. Kai Pinkernell, MD Chief Medical Officer, Chief Development Officer, Medigene AG and Dr. Peter van Balen, Internist-hematologist, Head of the Laboratory for Specialized Hematology, Leiden University Medical Center who will be talking about the industry and their expertise on the “Development of a TCR modified T-cell Immunotherapy in hematologic malignancies.

Go to registration page: https://attendee.gotowebinar.com/rt/6557235970600218637?source=Medicon+V...

 

TFS